A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 460 participants.

Also called NCT01455857

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 460 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01455857
Other papers using this trial's data
  • Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial Diabetes care, 2018-02 DOI, PubMed 29242349

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01455857. Randomized; quadruple masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
Intervention (Drug)
ITCA 650
Intervention (Other)
ITCA placebo
Lead sponsor
Intarcia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01455857
Content hash
3e4c38d06d64b8a29f43fb6b3260c53af086fede16b83dd52d62cd1c9af1e280